目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T63922 | |||
ERα degrader 5 是一种口服具有活力的、选择性的雌激素受体 (estrogen receptor (ER)) 降解剂,能够作用于 ERα (EC50: 1.1 nM)。ERα degrader 5 在体内显示抗肿瘤效果。 | |||
T64093 | |||
KRAS G12C inhibitor 44 是一种有效的、口服具有活力的 KRAS G12C 抑制剂。KRAS G12C inhibitor 44 在 MIA PaCA-2 (IC50: 0.016 μM)、H358 细胞 (IC50: 0.028 μM) 中表现出抗增殖作用。KRAS G12C inhibitor 44 在体内具有抗肿瘤活性。 | |||
T64028 | |||
Iruplinalkib 是一种选择性的、有效的、口服具有活力的 ALK 和 ROS1 酪氨酸激酶抑制剂。在伴有 ALK 或 ROS1 重排的晚期 NSCLC 中,Iruplinalkib 具有良好的安全性,并表现出抗肿瘤的潜能。 | |||
T63934 | |||
PAK4-IN-1 是一个选择性的、有效的、口服具有活力的 PAK4 抑制剂,在酸性和中性条件下都很稳定。PAK4-IN-1 在体内表现出良好的抗肿瘤作用。 | |||
T62763 | |||
VEGFR-2-IN-12 (compound 6g) 是一种 2-oxoquinoxalinyl-1,2,4-triazole,是一种 VEGFR-2 的有效抑制剂 (IC50: 0.037 μM)。VEGFR-2-IN-12 能够高度抑制 MCF-7 细胞的生长 (GI50: 1.6 μM)。VEGFR-2-IN-12 具有抗肿瘤作用。 | |||
T63103 | |||
PRMT5-IN-17 (Compound 6) 是一种 PRMT5 抑制剂,表现出抗肿瘤活性。其中 PRMT5 是一种蛋白质精氨酸甲基转移酶,是新型的与表观遗传修饰相关的抗肿瘤靶点。 | |||
T64259 | |||
GLS1 Inhibitor-5 (compound 24y) 是一种选择性的、口服具有活力的谷氨酰胺酶 1 (GLS1) 抑制剂 (IC50: 68 nM)。GLS1 Inhibitor-5 能够诱导细胞凋亡 (apoptosis),表现出抗肿瘤效果。 | |||
T62746 | |||
EGFR/HER2/CDK9-IN-1 (Compound 4) 是一种有效的 EGFR/HER2/CDK9 抑制剂,他们的 IC50 值分别为 90.17、131.39 和 67.04 nM。EGFR/HER2/CDK9-IN-1 表现出明显的抗肿瘤作用。 | |||
T64296 | |||
TIY-7 是一种选择性、口服具有活力的原肌球蛋白受体激酶 (TRK) 抑制剂。TIY-7 能够抑制 TRKA 酶 (IC50: 2.9 nM)、TRKAG595R 酶 (IC50: 1.1 nM)、TRKAG667C 酶 (IC50: 0.7 nM)、TRKAF589L 酶 (IC50: 0.8 nM)、TRKCG623R 酶 (IC50: 0.8 nM)、TRKCG696A 酶 (IC50: 0.2 nM)。TIY-7 在小鼠异种移植模型中表现出抗肿瘤效果。 | |||
T62598 | |||
Pitavastatin (NK-104) sodium 是一种有效的羟甲基戊二酰-CoA(HMG-CoA) 还原酶抑制剂,也是一种高效的肝细胞低密度脂蛋白胆固醇 (LDL-C) 受体诱导剂。Pitavastatin sodium 在 HepG2 细胞中,能够抑制乙酸合成胆固醇 (IC50: 5.8 nM) 。Pitavastatin sodium 表现出抗动脉粥样硬化、抗哮喘、抗骨关节炎、神经保护、抗肿瘤、肝保护和肾保护作用。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
|
|||||
TMPK-00456 | IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00455 | IGF1R/CD221 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00658 | IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 80.59 kDa (alpha subunit) and 19.28 kDa (beta subunit) and the accession number is G7P9I7.
|